Impact of Treatment Modality on Vascular Function in Coarctation of the Aorta: The LOVE - COARCT Study by Martins, JD et al.
Impact of Treatment Modality on Vascular Function in Coarctation of
the Aorta: The LOVE-COARCT Study
Jose D. Martins, MD, PhD; Justin Zachariah, MD, MPH; Elif Seda Selamet Tierney, MD; Uyen Truong, MD; Shaine A. Morris, MD, MPH;
Shelby Kutty, MD, PhD, MHCM; Sarah D. de Ferranti, MD, MPH; Maria Guarino, MD, PhD; Boban Thomas, MD; Diana Oliveira, MSc;
Antonio Marinho, MD; Marta Antonio, MD; Kimberlee Gauvreau, ScD; Nuno Jalles, MD; Tal Geva, MD; Miguel M. Carmo, MD, PhD;
Ashwin Prakash, MD; for the LOVE-COARCT Study*
Background-—Optimally treated patients with coarctation of the aorta remain at risk for late vascular dysfunction. The effect of
treatment modality on vascular function is unknown. The LOVE-COARCT (Long-term Outcomes and Vascular Evaluation After
Successful Coarctation of the Aorta Treatment) study was done to compare vascular function in patients with coarctation of the
aorta treated with surgery, balloon dilation (BD), or stent implantation.
Methods and Results-—In treated coarctation of the aorta patients without residual coarctation, we prospectively compared aortic
stiffness by applanation tonometry and cardiac magnetic resonance; endothelial function by endothelial pulse amplitude testing;
blood pressure (BP) phenotype by office BP, ambulatory BP monitoring, and BP response to exercise; left ventricular mass by cardiac
magnetic resonance; and blood biomarkers of endothelial function, inflammation, vascular wall function, and extracellular matrix.
Participants included 75 patients treated with surgery (n=28), BD (n=23), or stent (n=24). Groups had similar age at enrollment,
coarctation of the aorta severity, residual gradient, and metabolic profile, but differed by age at treatment. Prevalence of systemic
hypertension, aortic stiffness, endothelial function, and left ventricular mass were similar among treatment groups. However, BD
patients had more-distensible ascending aortas, lower peak systolic BP during exercise, less impairment in diurnal BP variation, and
lower inflammatory biomarkers. Results were unchanged after adjustment for potential confounders, including age at treatment.
Conclusions-—In our cohort of patients without residual coarctation, treatment modality was not associated with major vascular
outcomes, even though there were some favorable vascular characteristics in the BD patients. Although this suggests that choice
of treatment modality should continue to be driven by likelihood of achieving a good anatomical result, more long-term studies are
required to assess the clinical significance of the more-optimal results of secondary markers of vascular function in BD patients.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identifier: NCT03262753. ( J Am Heart Assoc. 2019;8:
e011536. DOI: 10.1161/JAHA.118.011536.)
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C urrent surgical and percutaneous techniques for treat-ment of coarctation of the aorta (CoA) are equally
effective at eliminating narrowing of the aortic isthmus,
except in infants and young children, in whom surgery
is preferred.1 However, despite optimal anatomical results,
late morbidity is significant with high rates of systemic
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hypertension.1 Secondary abnormalities, including increased
left ventricular (LV) mass2–5 and impaired systolic3,5 and
diastolic function,6 have also been reported. Furthermore,
treated patients have reduced life expectancy, attributed to
premature cardiovascular complications and stroke.7–9 Vas-
cular dysfunction is common after CoA treatment and may
contribute to these adverse outcomes.10–12 Patients with
successfully treated CoA have been reported to have stiffer
large arteries,3–5,11 impaired endothelial function,2,10,13,14 and
imbalances in biochemical and molecular pathways associ-
ated with vascular function.13–18 Although vascular dysfunc-
tion is driven by important pretreatment factors, including
abnormalities in the renin-angiotensin system19 and barore-
ceptor function,20 several treatment-related factors have been
associated with worse vascular dysfunction, such as older age
at treatment,3,10,16 longer length of follow-up, and residual
narrowing at the site of CoA repair.2
Several surgical and percutaneous techniques are available,
including resection and end-to-end anastomosis, balloon dila-
tion, and stenting. It is possible that treatment modality affects
vascular function by different effects on stiffness of the repaired
arterial segment: Surgical repair creates a focal scar at the site
of the surgical anastomosis; stenting creates a rigid, noncom-
pliant aortic segment; and balloon dilation (BD) produces a
controlled tear of the aortic intima and part of themedia without
affecting the adventitia.21 A few studies showed a better
vascular outcome with end-to-end anastomosis compared with
other surgical techniques22,23; however, the effect of treatment
modality on vascular function has not been systematically
compared. There are no randomized, prospective trials com-
paring the 3 treatment modalities for native CoA, although their
anatomical results and complications have been compared in
retrospective cohorts previously. Although the anatomical
outcomes and procedural adverse events of each treatment
modality have been well characterized, it is not known whether
they modulate late vascular dysfunction in different ways,
independent of anatomical results. Therefore, current manage-
ment is often guided by the patient’s age, anatomy, and
physician or institutional preference, with the primary goal of
alleviating the anatomical narrowing. The LOVE-COARCT (Long-
Term Outcomes and Vascular Evaluation After Successful
Coarctation of the Aorta Treatment) study compared optimally
patients successfully treated with surgery, BD, and stenting
with the aim to determinewhether choice of treatmentmodality
has an impact on late vascular function, independent of
anatomical results.
Methods
The data that support the findings of this study are available
from the corresponding author upon reasonable request.
Study Design and Subjects
In a multicenter, cross-sectional, observational study, patients
were recruited at 7 large pediatric cardiac centers in Europe
and North America between June 2013 and April 2017. We
included patients with (1) discrete isthmic CoA; (2) age at
recruitment 8 to 35 years; and (3) CoA treatment with end-to-
end surgical anastomosis, BD, or stent after 1994 and at least
6 months before enrollment. We excluded patients with (1)
residual CoA defined as a systolic upper-to-lower extremity
systolic blood pressure (SBP) gradient >20 mm Hg; (2)
comorbidities, including complex congenital heart disease
(such as tricuspid atresia), vasculopathy, or genetic syndrome;
(3) CoA treatment using >1 modality; (4) severe hypoplasia of
the transverse aortic arch (z-score < 4); (5) other cardiac
defects requiring intervention (such as ventricular or atrial
septal defect, valvar mitral, or aortic stenosis); (6) treatment
under 1 year of age (because these patients are treated
almost exclusively with surgery); and (7) long segment
coarctation. We attempted to frequency match the 3 treat-
ment groups on age at initial repair and age at enrollment.
Study data were collected and managed centrally using
REDCap (Research Electronic Data Capture) electronic data
capture tools.24 The study protocol was approved by the
institutional review board or institutional ethics committee at
each participating center. Written consent was obtained from
each participant or parent, as appropriate.
Study Tests
All study tests occurred during a 1- or 2-day visit. Vascular
function was assessed comprehensively by several modalities.
Clinical Perspective
What Is New?
• It is unknown whether treatment modality in coarcation
patients affects vascular function, by having different effects
on the stiffness of the repaired arterial segment.
• We found that, in optimally treated coarctation of aorta
patients, treatment modality was not associated with major
vascular outcomes, including systemic hypertension, global
aortic stiffness, and endothelial function.
• However, there were some favorable vascular characteris-
tics in balloon dilation patients.
What Are the Clinical Implications?
• Until prospective long-term comparisons of comprehensive
anatomical and vascular outcomes between modalities
become available, choice of treatment modality should
continue to be driven by likelihood of achieving the most
optimal anatomical result.
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Testing included assessment of (1) arterial stiffness by
applanation tonometry and cardiac magnetic resonance imag-
ing (CMR), (2) endothelial function by endothelial pulse
amplitude testing (Endo-PAT), and (3) blood pressure (BP)
phenotype using office BP measurement, ambulatory BP
monitoring (ABPM) and BP response during peak exercise,
and blood biomarkers related to endothelial function, systemic
inflammation, and vascular remodeling.
Applanation Tonometry
Studies were performed using the NIHem (Cardiovascular
Engineering, Inc, Norwood, MA) or the SphygmoCor device
(AtCor Medical, West Ryde, NSW, Australia) to calculate
carotid-femoral pulse wave velocity (PWV) using standard
technique as previously described.25 The NIHem system
determines central aortic pressure as equivalent to measured
carotid pulse waveform, calibrated by the brachial waveform
to the brachial diastolic BP (DBP) and mean BP. For tracings
obtained using the SphygmoCor device, the signal averaged
carotid pulse wave was digitalized and calibrated according to
a previously published approach to allow a quantitative
analysis of the pulse waveform.26 Comparability of the
2 approaches as described above has been previously
established.27
Cardiac Magnetic Resonance Imaging
Examinations were performed using commercially available
whole-body 1.5 Tesla scanners (Achieva; Philips Healthcare,
Best, the Netherlands; Signa 1.5T or GE Medical Systems,
Milwaukee, WI). Images were analyzed by a single observer
(A.P.) in the CMR core lab using a commercial computer
workstation (Extended Workstation; Philips Healthcare) and
commercially available analysis software (QMass and QFlow;
Medis, Leiden, the Netherlands). Right brachial artery BP was
measured before the examination in the supine position by
using commercial oscillometric BP recorders. LV function and
mass were measured using ECG-gated steady-state free
precision image in the ventricular short axis as previously
described.25 Segmental aortic stiffness (strain, distensibility,
and b stiffness index) were calculated using cine steady-state
free precision images in the short axis of the ascending aorta
(AAO), proximal descending aorta (DAO; 2–3 cm distal to the
isthmus, sufficiently distal to dephasing jets), mid DAO
(diaphragmatic level), and distal DAO (just above iliac
bifurcation) using a previously described methodology.25
The isthmus was defined as the segment immediately distal
to the origin of the left subclavian artery. Global and
segmental PWV were calculated using the transit-time
method using ECG-gated through-plane phase-contrast flow
measurements at the AAO and proximal, mid, and distal DAO
segments (matched to location of the cine steady-state free
precision acquisitions) as previously described.25 Temporal
resolution was maximized by reconstructing 100 cardiac
phases and using a turbo factor/views-per-segment setting of
1. ECG and respiratory navigator-gated 3-dimensional steady-
state free precision magnetic resonance angiography of the
aortic arch was performed in the sagittal plane. Aortic arch
shape and the aortic arch index were obtained as previously
described.25
Endothelial Function
Flow-dependent, endothelium-mediated vasodilation was
assessed using Endo-PAT (Itamar Medical, Caesarea, Israel)
as previously described.25 Endo-PAT is a novel noninvasive
and reproducible technique that measures changes in
pulsatile arterial volume with a fingertip probe. Analysis of
the pulse waveform allows for automated calculation of
endothelial function in 1 arm, while the contralateral serves as
a control. Endo-PAT has been validated in adults to identify
patients with coronary endothelial dysfunction with good
sensitivity and specificity,28 and has been shown to be
feasible and reproducible in adolescents.29
BP Phenotype
The seated right arm office BP was measured after 5 minutes
of quiet rest using the manual auscultation technique with
arm supported and feet flat on the floor. Three recordings
were obtained, allowing 1 minute between deflation and
reinflation of the cuff. The BP was recorded as the average of
the second and third measurements. BP was classified
according to the 4th Task Force report for children30 and
the 7th Report of the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure
for adults (Table S1).31 Supine, oscillometric 4-extremity BP
was used to assess for residual coarctation defined as the
difference between the right arm SBP and the highest SBP in
either leg.
Home ABPM was performed using a previously described
technique.25 The examination was considered adequate if the
recording lasted >12 hours. BP averages and proportion of
elevated readings (load) were calculated and categorized
according to the age-based normative guidelines previously
established for children32 and adults.33 Patients were staged
as having ambulatory hypertension, masked hypertension,
white coat hypertension, or normotensive (Table S2).
Patients performed an exercise stress test using the
standard Bruce treadmill protocol to assess BP response
to exercise, as previously described.25 Baseline and peak
arm-leg SBP differences and the increase in right-arm BP
with peak exercise were recorded. Gas exchange during
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exercise was assessed in a subset of patients, when
feasible.
Blood Biomarkers
Patients followed a low-nitrate diet for 3 days and fasted for
12 hours before sample collection. We measured biomarkers
of nitrate metabolism as regulators of endothelial function
(nitrite/nitrate [NOx] and asymmetric dimethylarginine
[ADMA])34,35; systemic inflammation (high-sensitivity C-reac-
tive protein [hs-CRP] and interleukin 1 beta)36,37; vascular wall
function (vascular adhesion molecule 1)36; and extracellular
matrix remodeling (matrix metalloproteases [MMP]-2 and
MMP-9 and transforming growth factor beta-1 [TGF-b1]).38
NOx was determined by chemiluminescence (Sievers NOAn-
alyzer 280i), and all remaining measurements were performed
using commercial ELISA kits: ADMA (Sunred Biological
Technology, Shanghai, China); hs-CRP (BoosterBio, Pleasan-
ton, CA); vascular adhesion molecule 1; interleukin 1 beta;
MMP-9; MMP-2; and TGFb-1 (RayBiotech, Inc, Norcross, GA).
All measurements were performed as previously described,25
at the central biomarker laboratory in Lisbon.
Statistical Analysis
Sample-size estimates were obtained based on previous
reports of arch PWV measured by CMR in normal subjects
(3.30.6 m/s) and in patients with CoA (4.71.1 m/s).4,39
Sample-size estimates for comparison of CMR PWV between
3 equal-sized treatment groups (assuming an overall signif-
icance level of 0.05 and power of 0.8) are shown in Table S3).
Using these estimates, we planned on recruiting 24 to 30
patients in each treatment group.
Categorical patient characteristics, clinical variables, and
outcomes are summarized as frequencies and percentages
and were compared across the 3 treatment groups using
Fisher’s exact test. Continuous variables that were approxi-
mately normally distributed were summarized using means
and SDs and compared using 1-way ANOVA; continuous
variables that were not normally distributed were summarized
using medians and ranges and compared using the Kruskal–
Wallis test. Age at treatment and presence of a bicuspid aortic
valve (known to be associated with impaired aortic elastic-
ity)40 were thought to be possible confounding variables and
were observed to differ by treatment group; therefore, linear
and logistic regression models were used to adjust for
confounding when comparing selected outcome variables
across treatment groups. In these models, the surgical group
was used as the reference category against which balloon
dilation and stent were compared. Each model adjusted for
age at treatment as a continuous variable and presence of a
bicuspid aortic valve as a binary variable. Analyses were




Patient characteristics by treatment group are summarized in
Table 1. At study enrollment, treatment groups were similar
with respect to baseline characteristics, including age and
body mass index at enrollment, residual coarctation severity,
and metabolic profile. Site of enrollment was not a predictor
of age at treatment, current age, sex, or type of treatment.
Among pretreatment characteristics, treatment groups were
similar with respect to coarctation severity (including size of
the aortic arch and isthmus, noninvasive BP, and echo-
Doppler estimated gradient), sex distribution, and prevalence
of bicuspid aortic valve. However, patients treated with a
stent were older at time of treatment compared with those
treated with surgery or BD.
Aortic Stiffness
Results of aortic stiffness assessment by CMR and applana-
tion tonometry are summarized in Table 2 and Figure. At
comparable distending pressures (Table 3), overall PWV was
similar among treatment groups by both CMR and applanation
tonometry (Figure). On segmental PWV measurements by
CMR, aortic arch PWV was lowest in the BD group, but the
difference did not reach statistical significance (Figure).
Among CMR segmental aortic stiffness parameters, BD
patients had the most distensible AAO, whereas stent
patients had the least distensible AAO, with surgical patients
demonstrating intermediate values (Figure). Compared with
stent patients, BD patients showed 48% higher AAO disten-
sibility and 27% lower aortic arch PWV. In contrast, segmental
stiffness parameters were mostly similar across treatment
groups at the DAO (proximal, mid, and distal), except for distal
DAO strain, which was lowest in the stent group. No
differences were observed across treatment groups in
measurements of central SBP or central pulse pressure by
tonometry. Augmentation index at heart rate 75 bpm was
similar among groups.
To assess for potential confounding by age at treatment
or bicuspid aortic valve (known to be associated with
impaired aortic elasticity)40 on the relationship between
treatment modality and aortic stiffness, we used multivari-
able modeling for key stiffness parameters. Univariate
relationships shown in Table 2 remained unchanged in
multivariable models after adjustment for potential con-
founding variables (age at treatment and bicuspid aortic
valve; Tables S4 through S6).
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Endothelial function assessed using the Endo-PAT index was
similar across treatment groups (Table 2 and Figure). Uni-
variate relationships shown in Table 2 remained unchanged in
multivariable models after adjustment for potential confound-
ing variables (age at treatment and bicuspid aortic valve;
Table S6).
BP Phenotype
Results of office BP measurements and ABPM are summarized
in Table 3. There were no significant differences across
treatment groups with respect to prevalence of hypertension
by office measurements or ABPM, and average systolic and
DBP by ABPM. However, the BD group showed lower
nighttime BP and less impairment in diurnal variation,
compared with the stent and surgery groups (Figure). On
exercise stress test (Table 4), there were no significant
differences between treatment groups with respect to exer-
cise duration, peak VO2, VE/VCO2 slope, or upper-lower
extremity SBP gradient. However, peak SBP during exercise
was lower in the BD group (Figure), and this relationship
persisted after adjustment for potential confounding variables
(age at treatment and bicuspid aortic valve; Table S6).
LV and Aortic Morphometrics
Treatment groups were similar with respect to LV size, ejection
fraction, and mass (Table 5 and Figure). Aortic dimensions,
including those of the transverse aortic arch, were similar
between treatment groups. Isthmic dimensions were slightly
smaller in the BD group compared with the surgical group, but
could not be measured in stented patients because of
ferromagnetic artifact from the stent. Arch shape distribution
was also similar between treatment groups, assessed both
qualitatively and quantitatively (using the Arch Shape Index).
Table 1. Patient Characteristics
Surgery (n=28) BD (n=23) Stent (n=24) P Value
Pretreatment data
Age at treatment, y 6 (1, 26) 5 (1, 17) 15 (7, 26) <0.001
SBP gradient, mm Hg 43.719.3 34.615.0 38.421.0 0.29
TAA diameter z-score 1.91.0 1.51.4 1.90.8 0.38
Isthmus diameter z-score 3.591.21 3.920.89 3.311.37 0.32
Initial Doppler gradient, mm Hg 48.014.7 47.914.8 52.520.3 0.60
Male sex 79% 74% 75% 0.94
Bicuspid aortic valve 71% 45% 50% 0.13
Age at enrollment, y 15 (8, 33) 17 (11, 26) 20 (9, 33) 0.12
BMI at enrollment 22 (15, 32) 21 (16, 33) 23 (16, 38) 0.69
SBP gradient, mm Hg 7.114.0 3.012.3 3.714.5 0.52
NYHA class
I 89% 100% 92% 0.37
II 11% 0% 8%
Metabolic profile
Total cholesterol, mg/dL 159 (112, 210) 153 (123, 229) 152 (108, 227) 0.59
LDL, mg/dL 86 (53, 145) 81 (59, 179) 85 (44, 130) 0.66
HDL, mg/dL 53 (34, 90) 48 (31, 90) 51 (32, 88) 0.99
Triglycerides, mg/dL 76 (29, 224) 52 (29, 149) 74 (29, 167) 0.07
Plasma glucose, mg/dL 82 (74, 98) 81 (59, 93) 86 (63, 108) 0.15
Insulin, lIU/mL 6 (3, 44) 6 (3, 17) 7 (2, 20) 0.86
Hemoglobin A1c, % 5.3 (4.1, 5.7) 5.3 (4.4, 5.7) 5.3 (4.8, 5.9) 0.60
Antihypertension medication 14% 26% 33% 0.14
Values are meanSD, median (minimum, maximum), or percent. BMI indicates body mass index (weight (kg)/height (m)2); BSA, body surface area; HDL, high-density lipoprotein; LDL, low-
density lipoprotein; NYHA, New York Heart Association; SBP, systolic blood pressure; TAA, transverse aortic arch.
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Patients in the BD group had lower levels of hs-CRP and
higher levels of MMP-9 and TGF-b1 (Table 6 and Figure).
These differences persisted after adjustment for potential
confounders (Table S6). Levels of other blood biomarkers
were similar across treatment groups.
Adjustment for Potential Confounders
As seen in Table 1, despite efforts at frequency matching, there
were differences between treatment groups with respect to
potential confounding variables, including age at treatment and
presence of a bicuspid aortic valve. Analyses to assess the impact
of these confounding variables are summarized in Tables S4
through S6. As seen in Table S4, age at treatment was
significantly associated with AAO strain, Endo-PAT index, right-
arm DBP, and 24-hour DBP, but not with other key outcome
variables. As seen in Table S5, presence of the bicuspid aortic
valve was significantly associated with AAO strain, but not with
other outcome variables. Table S6 summarizes the results of
multivariable modeling, comparing key outcome variables
between treatment groups while adjusting for these cofounding
variables (age at treatment and presence of bicuspid aortic valve).
Adjusted and unadjusted models did not differ significantly for
Table 2. Aortic Stiffness and Endothelial Function
Surgery (n=28) Balloon Dilation (n=23) Stent (n=24) P Value
CMR parameters
PWV, m/s
Total 4.00.5 4.20.9 4.20.7 0.72
Aortic arch 4.71.5 4.01.2 5.53.8 0.12
Mid DAO 3.80.9 4.01.3 3.91.4 0.87
Distal DAO 4.41.6 4.81.7 4.51.5 0.70
Strain
AAO 0.380.14 0.510.25 0.360.19 0.02
Proximal DAO 0.270.09 0.310.13 0.300.15 0.47
Mid DAO 0.370.11 0.360.10 0.360.16 0.97
Distal DAO 0.370.14 0.400.12 0.300.12 0.04
Distensibility (103 mm Hg 1)
AAO 7.83.6 9.85.2 6.64.3 0.05
Proximal DAO 5.62.1 6.13.3 5.62.7 0.71
Mid DAO 7.52.5 6.93.3 6.83.4 0.67
Distal DAO 7.84.1 7.53.1 5.93.2 0.15
b stiffness index
AAO 1.760.73 1.591.15 2.491.48 0.02
Proximal DAO 2.531.59 2.631.89 2.500.96 0.96
Mid DAO 1.750.76 1.930.75 2.151.11 0.26
Distal DAO 1.840.91 1.720.68 2.983.70 0.11
Applanation tonometry
cfPWV, m/s 5.20.9 5.31.1 5.00.9 0.64
AI at HR 75 bpm, % 1413 1321 618 0.24
Central SBP, mm Hg 11418 10914 11221 0.60
Central PP, mm Hg 5020 4613 4519 0.49
Endo-PAT
Endo-PAT index 2.150.77 2.000.78 2.250.68 0.51
Values are meanSD. AAO indicates ascending aorta; AI, augmentation index; aortic arch PWV, AAO to proximal DAO pulse wave velocity; cfPWV, carotid-femoral pulse wave velocity;
DAO, descending aorta; Endo-PAT, endothelial pulse amplitude testing; HR, heart rate; PP, pulse pressure; SBP, systolic blood pressure; total PWV, AAO to distal DAO pulse wave velocity.
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these key outcome variables, suggesting that the impact of these
potential confounding variables on our study measurements was
not significant.
Discussion
In this multicenter, cross-sectional, observational comparison of
vascular function in selected patients with CoA treated with
surgery, BD, or stenting without residual coarctation, we found
that major vascular outcomes (prevalence of systemic hyperten-
sion, global aortic stiffness, central BP, endothelial function, and
LV mass) following coarctation treatment were similar across
treatment modalities. There were some favorable secondary
vascular characteristics in BD patients. However, the significance
of these findings in the absence of differences in rates of systemic
hypertension and LV hypertrophy remains unclear.
Aortic Stiffness
Global aortic stiffness assessed using carotid-femoral PWV by
tonometry, or using total aortic PWV by CMR, was higher than
published normal values, but was similar among treatment
Figure. Comparison of key vascular function parameters between groups. Box and whisker plot of selected study variables. Boxes represent
mean2 SDs, and whiskers represent minimum and maximum values. Blue is balloon dilation; red is surgery; and green is stent. AAO indicates
ascending aorta; BSA, body surface area; cfPWV, carotid-femoral pulse wave velocity; CMR, cardiac magnetic resonance; Endo-PAT, endothelial
pulse amplitude testing; hs-CRP, high-sensitivity C-reactive protein; IL-1b, interleukin 1 beta; LV, left ventricle; MMP-9, matrix metalloprotease 9;
PWV, pulse wave velocity; SBP, systolic blood pressure; TGF-b1, transforming growth factor beta-1.
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groups.41 However, in segmental assessment of PWV and
other distensibility measures by CMR (strain, distensibility,
and b stiffness index), differences emerged between treat-
ment groups. Proximal aortic (AAO and aortic arch) stiffness
was lowest in BD patients and highest in stent patients.
Surgical patients had intermediate values of stiffness. AAO
distensibility in BD patients was similar to values reported in
normal controls, whereas patients in the stent and surgery
Table 3. Blood Pressure Phenotype
Surgery (n=28) Balloon Dilation (n=23) Stent (n=24) P Value
Office BP 0.20
Normal 15 (54%) 13 (57%) 7 (29%)
Prehypertension 10 (36%) 8 (35%) 15 (63%)
Stage 1 hypertension 3 (11%) 2 (9%) 1 (4%)
Stage 2 hypertension 0 (0%) 0 (0%) 1 (4%)
ABPM
24-hour average SBP, mm Hg 12313 1189 12410 0.19
24-hour average DBP, mm Hg 688 666 688 0.77
Day average SBP, mm Hg 12513 12210 12710 0.34
Day average DBP, mm Hg 699 697 719 0.82
Night average SBP, mm Hg 11612 10610 11310 0.005
Night average DBP, mm Hg 607 565 594 0.05
% SBP readings above diurnal threshold 3229 1919 3027 0.19
% DBP readings above diurnal threshold 1620 1314 1416 0.72
Diurnal systolic variation, % 77 136 116 0.01
Diurnal diastolic variation, % 1310 196 167 0.06
Nondippers (%) 17 (65%) 7 (32%) 12 (55%) 0.08
Classification by ABPM 0.76
No hypertension 16 (59%) 18 (82%) 15 (68%)
White coat hypertension 3 (11%) 1 (5%) 1 (5%)
Masked hypertension 6 (22%) 2 (9%) 5 (23%)
Hypertension 2 (7%) 1 (5%) 1 (5%)
Classification including medication use
Hypertension/masked hypertension, or antihypertension medication 8 (30%) 9 (39%) 10 (45%) 0.49
Values are meanSD, or n (%). ABPM indicates ambulatory blood pressure measurement; BP, blood pressure; CMR, cardiac magnetic resonance imaging; DBP, diastolic blood pressure;
Dippers, nighttime BP dipping ≥10%; LV, left ventricle; nondippers, nighttime BP dipping <10%; SBP, systolic blood pressure.
Table 4. Exercise Stress Test
Surgery (n=28) Balloon Dilation (n=23) Stent (n=24) P Value
Exercise duration, min 12 (7, 21) 11 (9, 21) 13 (5, 17) 0.45
Pre-exercise SBP gradient, mm Hg 321 19 618 0.17
Peak-exercise SBP gradient, mm Hg 3230 3322 2627 0.64
Peak right arm SBP, mm Hg 17735 15727 17733 0.05
Peak right arm DBP, mm Hg 7113 759 7311 0.50
VO2 max, mL/kg/min 4111 3227 4111 0.30
VE/CO2 slope 264 265 266 0.98
Values are meanSD, or median (minimum, maximum). DBP indicates diastolic blood pressure; SBP, systolic blood pressure; VE/CO2, relationship between ventilation and CO2 output;
VO2 max, peak exercise oxygen consumption.
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groups had lower values.41 These findings were limited to the
AAO, which is in line with previous studies that show that the
aortic elastic properties have been found to be altered above,
but not below, the CoA site, compared with normals.5
Increased proximal aortic stiffness evidenced by an elevated
PWV and lower-than-normal distensibility have been previously
reported in patients with CoA.4,10,11 However, our study is the
first to systematically compare aortic stiffness across treat-
ment modalities. The mechanism leading to a more-distensible
proximal aorta in balloon dilation patients remains unclear. It is
possible that absence of a surgical scar or rigid stent at the
isthmus contributes to a lower stiffness at the CoA site.
However, the significance of this finding remains unclear in the
context of similar rates of hypertension and LV mass across
treatment groups. It should also be noted that the BD group
underwent treatment at a younger age; however, differences in
AAO stiffness persisted after adjustment for age at treatment.
Endothelial Function
Flow-dependent, endothelium-mediated peripheral artery func-
tion and vasodilation was assessed using Endo-PAT. Results of
previous studies of endothelial function in patients with CoA
have been mixed. Some studies showed impaired endothelium-
dependent vascular reactivity,10,42,43 whereas others showed
preserved vascular reactivity.44,45 Our results showed that the
Table 5. CMR LV and Aortic Measurements
Surgery (n=28) Balloon Dilation (n=23) Stent (n=24) P Value
LV measurements
EDV, mL/m2 7113 7617 7318 0.64
Ejection fraction, % 636 615 625 0.52
Mass, g/m2 5613 589 5713 0.83
Aortic diameters (mm/BSA0.5)
Ascending aorta 19.13.0 20.63.2 20.73.4 0.18
Proximal transverse arch 12.61.2 12.81.8 12.72.9 0.96
Distal transverse arch 11.51.7 11.21.6 11.92.1 0.45
Isthmus 12.63.7 10.42.8 N/A* 0.03
Descending aorta 12.41.1 12.61.8 12.51.6 0.95
Arch shape 0.33
Romanesque 11 (39%) 10 (43%) 10 (42%)
Crenel 2 (7%) 5 (22%) 2 (8%)
Gothic 14 (50%) 6 (26%) 12 (50%)
Arch Shape Index 0.640.14 0.650.11 0.680.13 0.64
Values are meanSD, or number (percent). Arch Shape Index indicates aortic arch height divided by width; BSA, body surface area; CMR, cardiac magnetic resonance imaging; EDV, end-
diastolic volume; LV, left ventricular.
*N/A=not available, because of presence of stent artifact.
Table 6. Blood Biomarkers
Surgery (n=28) Balloon Dilation (n=23) Stent (n=24) P Value
NOx, lg/mL 18 (12, 31) 20 (12, 37) 20 (10, 34) 0.18
ADMA, ng/L 6 (1, 45) 7 (1, 51) 3 (0, 31) 0.20
hs-CRP, mg/L 1.28 (0.74, 1.49) 1.26 (0.66, 1.41) 1.30 (0.95, 1.46) 0.02
VCAM-1, ng/mL 133 (66, 203) 134 (61, 206) 128 (66, 168) 0.42
IL-1b, pg/mL 0.91 (0.04, 1.26) 1.06 (0.68, 1.98) 0.95 (0.06, 1.49) 0.1
TGF-b1, ng/mL 0.35 (0.12, 1.24) 0.64 (0.23, 3.21) 0.31 (0.05, 2.07) 0.006
MMP-2/gelatinase A, ng/mL 1.14 (0.10, 3.37) 1.53 (0.00, 4.93) 0.62 (0.00, 3.62) 0.26
MMP-9/gelatinase B, ng/mL 474 (91, 3157) 738 (158, 4453) 421 (487, 1739) 0.01
Values are median (minimum, maximum). ADMA indicates asymmetric dimethylarginine; hs-CRP, high-sensitivity C-reactive protein; IL-1b, interleukin 1 beta; MMP, matrix metalloprotease;
NOx, nitrite/nitrate; TGF-b1, transforming growth factor beta-1; VCAM-1, vascular adhesion molecule 1.
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Endo-PAT index was similar across treatment groups, and
suggest that endothelial function is preserved after CoA
treatment, compared with previously reported values in healthy
controls.46 Values obtained in our cohort are comparable with
those reported using a similar technique in patients with CoA.44
BP Phenotype
Prevalence of hypertension on office measurement and ABPM
were similar to previous reports.1,47–49 There were no
differences between treatment groups with respect to preva-
lence of hypertension (on office measurements and ABPM) or
the average 24-hour systolic or DBP. However, in other
parameters on ABPM, BD patients demonstrated lower
nighttime SBP and DBP, and more physiological nighttime
dipping in BP, compared with the surgery and stent groups.
Our results are consistent with a previous report that found
lower BP in BD patients.1 Blunted nighttime dipping in BP has
been previously linked to development and progression of
end-organ disease in patients with essential hypertension,
diabetes mellitus, obesity, and black race.50 In the absence of
differences in LV mass, the significance of this finding on
long-term outcomes in CoA patients deserves further study.
The BD group showed a less-exaggerated BP elevation to
exercise, compared with the surgery and stent groups.
Exercise-induced hypertension has been previously docu-
mented in patients with treated CoA,51 and exaggerated BP
response to exercise correlated with LV mass.52 In the
general population, exercise-induced hypertension has been
shown to be predictive of future development of resting
hypertension53 and an independent risk factor for cardiovas-
cular events and mortality.54 However, LV mass was similar
across treatment groups in our study population.
LV and Aortic Morphometrics
Despite differences in BP phenotype, LV mass was similar
across treatment groups, and values were normal compared
with previously reported values in healthy subjects.55 Increased
LV mass has been previously reported in patients with CoA.4
Our LV mass values were lower compared with this previous
report, but are similar to a more-recent publication.49 Absence
of significant LV hypertrophy may be related to the relatively
young age of our patients and good BP control in our population.
Our findings suggest that despite minor differences in sec-
ondary parameters of vascular function, there are no significant
difference in LV remodeling across treatment groups.
Blood Biomarkers
NOx and ADMA are biomarkers related to endothelial
function, and their levels have been correlated with risk of
atherosclerosis attributed to endothelial-dependent nitric-
oxide regulation of smooth-muscle–derived vascular tone.34
There were no differences in NOx or ADMA levels between
treatment groups, consistent with the lack of difference in
endothelial function using Endo-PAT. Previous studies in
patients with CoA found increased ADMA, but unchanged
NOx, in CoA compared with controls.13
Interleukin 1 beta and hs-CRP are biomarkers of systemic
inflammation, which act on the vascular endothelium to
upregulate a number of adhesion molecules, such as vascular
adhesion molecule, with a crucial role in atherogenesis.36,37
There is a strong association between hs-CRP and risk of
cardiovascular disease, but, despite multiple trials, there
remains a lack of consensus regarding its clinical use, namely
the cut-off value for increased risk.56 Past results of
inflammatory biomarkers in patients with CoA are inconclu-
sive.57,58 In our study, BD patients had lower levels of hs-CRP.
TFG-b1, MMP-2, and MMP-9 are biomarkers related to
fibrotic remodeling, such as the aortic remodeling, that occurs
in response to hemodynamic changes.38 Elevated circulating
levels have been reported in dilated aortas in patients with
inherited aortopathy59 and are biomarkers for the presence
and risk of rupture of aortic aneurysm.60 As previously
reported in patients with CoA, values of both TFG-b1and
MMP-9 were elevated in our study, compared with previously
reported values in healthy controls.16,61 BD patients showed
the highest levels of these biomarkers. Experimental studies
showed that increased aortic wall motion is associated with a
higher risk of aneurysm formation,62 which could explain our
results in BD, who have an increased AAO strain and higher
MMP-9 values. However, the clinical implications of these
findings are unclear, and further research is needed to
evaluate whether these biomarkers are related to the risk of
aneurysm formation in the BD group.
Study Limitations
There are several limitations to our study. First, our study
group represents a selected group of CoA patients without
residual narrowing that only had treatment with 1 modality.
We specifically chose this population to allow comparison of
vascular function without confounding by differences in
anatomical results among modalities. Our study was not
designed to compare anatomical outcomes, such as rates of
restenosis, reintervention, and aneurysm formation, that have
been previously described.1 Second, although we attempted
to perform frequency matching to balance the treatment
groups with respect to key confounding variables, our groups
were not perfectly matched for age at treatment. Multivariable
analyses (Table S6) showed that these potential confounding
variables (including age at repair) did not significantly affect
the comparison of key variables between treatment groups,
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but these analyses may be limited by small group sizes. Third,
stent patients had a shorter follow-up duration than surgical
and BD patients, which could have impacted their vascular
outcomes. However, no patients were recruited until
6 months after intervention, which likely mitigated this effect.
Finally, we did not collect information on race/ethnicity and
therefore cannot comment on their effect on our results.
Conclusions
In this multicenter, cross-sectional, observational comparison
of vascular function in selected patients with CoA treated with
surgery, BD, or stenting without residual coarctation, we
found that major vascular outcomes following coarctation
treatment were similar across treatment modalities, even
though there were some favorable vascular characteristics in
BD patients. The significance of these finding in the absence
of differences in rates of systemic hypertension and LV
hypertrophy remains unclear. Until prospective long-term
comparisons of comprehensive anatomical and vascular
outcomes between modalities become available, choice of
treatment modality should continue to be driven by likelihood
of achieving the most optimal anatomical result.
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Table S1. Office BP Classification. 
Classification  SBP DBP 
Normal children: < 90th %tile 
adults: <120mm Hg 
children: < 90th %tile 
adults: and <80mHg 
Pre-HTN children:  90th to 95th %tile or if BP 
exceeds 120/80mm Hg even if 90th 
%tile up to  95th percentile 
adults: 120-139mm Hg 
children:  90th to 95th %tile or if 
BP exceeds 120/80 even if 90th 
percentile up to  95th %tile 
adults: or 80–89mm Hg 
Stage 1 HTN children: 95th–99th %tile plus 5mm 
Hg 
adults: 140-159mm Hg 
children: 95th–99th %tile plus 5mm 
Hg 
adults: or 90–99mm Hg 
Stage 2 HTN children:  99th %tile plus 5mm Hg 
adults: ≥160mm Hg 
children:  99th %tile plus 5mm Hg 
adults: or >100mm Hg 
%tile = percentile; DBP = diastolic blood pressure; HTN = hypertension; SBP = systolic blood 
pressure; for children (<18yo), based on table 5 (classification of BP) and table 3 (normative 
values) of the National High Blood Pressure Education Program Working Group on High Blood 
Pressure in C, Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high 
blood pressure in children and adolescents;25 For adults (>= 18yo), based on table 3 
(classification of BP) of the 7th Report of the Joint National Committee on the Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure report.26  
Table S2. Classification of HTN with ABPM. 
Classification Office BP SBP or DBP * 24h Mean ABPM SBP or 
DBP † 
No hypertension Pediatric: <95th %tile 
Adults: <140/90 mm Hg 
Pediatric: <95th %tile 
Adults: <135/85 mm Hg 
White Coat Hypertension Pediatric: ≥95th %tile 
Adults: >140/90 mm Hg 
Pediatric: <95th %tile 
Adults: <135/85 mm Hg 
Masked Hypertension Pediatric: <95th %tile 
Adults: <140/90 mm Hg 
Pediatric: >95th %tile 
Adults: >135/85 mm Hg 
Ambulatory Hypertension Pediatric: >95th %tile 
Adults: >140/90 mm Hg 
Pediatric: >95th %tile 
Adults: >135/85 mm Hg 
ABPM = Ambulatory blood pressure monitoring; BP = Blood Pressure; ABPM = Ambulatory 
Blood Pressure Monitoring; Pediatric patients have age <18yo and adult patients age ≥18yo; 
%tile = percentile; BP = blood pressure; DBP = diastolic blood pressure; and SBP = systolic 
blood pressure. *For pediatric patients, based on the normative data of the National High Blood 
Pressure Education Program Working Group on High BP in C, Adolescents. The fourth report on 
the diagnosis, evaluation, and treatment of high BP in children and adolescents;25 for adult 
patients, based on the 7th Report of the Joint National Committee on the Prevention, Detection, 
Evaluation, and Treatment of High BP report.26 † For pediatric patients, based on normative 
pediatric ABPM values from the American Heart Association Atherosclerosis, Hypertension and 
Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young; 27 for adult 
patients, based on the Subcommittee of Professional and Public Education of the American Heart 
Association Council on High Blood Pressure Research report.60  











4.0 4.8 1.0 30 90 
4.0 4.8 1.1 36 108 
4.0 4.8 1.2 43 129 
4.4 5.3 1.0 24 72 
4.4 5.3 1.1 29 87 
4.4 5.3 1.2 34 102 
PWV = pulse wave velocity 
  
Table S4. Assessment for Confounding by Age at Treatment. 
Values are mean ± standard deviation, number (percent), or median (minimum; maximum). 
AAO = Ascending aorta; AI = Augmentation index; cfPWV = carotid-femoral pulse wave 
velocity; DBP = Diastolic blood pressure; Endo-PAT = Endothelial pulse amplitude testing; hs-
CRP = High sensitivity C-reactive protein; HTN = Hypertension; MMP = matrix 
metalloprotease; MRI = Magnetic resonance imaging; PWV = Pulse wave velocity; SBP = 
Systolic blood pressure.  
  1-3 4-9 10-14 15 p Value 
MRI proximal PWV (m/s) 4.8 ± 2.1 4.2 ± 1.1 5.6 ± 4.4 4.9 ± 1.3 0.35 
AAO strain (%) 0.48 ± 0.24 0.44 ± 0.16 0.45 ± 0.24 0.28 ± 0.15 0.02 
cfPWV (m/s)  5.4 ± 1.1 4.8 ± 0.8 5.4 ± 1.1 5.3 ± 0.9 0.13 
AI (%) -12 ± 14 -14 ± 20 -7 ±18 -3 ± 19 0.21 
Endo-PAT index 1.85 ± 0.55 1.89 ± 0.72 2.50 ± 0.73 2.34 ± 0.75 0.02 
Right arm SBP (mm Hg) 121 ± 14 117 ± 12 124 ± 13 123 ± 12 0.34 
Right arm DBP (mm Hg)   61 ± 5    63 ± 9    69 ± 11 68 ± 11  0.05 
24-hour average SBP (mm Hg) 119 ± 14 120 ± 11 124 ± 8  126 ± 10 0.20 
24-hour average DBP (mm Hg)   66 ± 8  64 ± 7    69 ± 7 71 ± 8  0.04 
Hypertension Classification     0.14 
   No HTN   7 (58%) 19 (70%) 9 (53%)   6 (35%)  
   White coat HTN 1 (8%) 1 (4%) 2 (12%) 1 (6%)  
   HTN/Masked HTN/Anti HTN meds 4 (33%) 7 (26%) 6 (35%) 10 (59%)  
Peak exercise right arm SBP (mm 
Hg) 
161 ± 34 169 ± 35 170 ± 27 180 ± 33 0.47 
hs-CRP (mg/L) 127 (104, 146) 127 (66, 143) 129 (86, 149) 128 (98, 146) 0.67 







Table S5. Assessment for Confounding by Presence of Bicuspid Aortic Valve. 
Values are mean ± standard deviation, number (percent), or median (minimum; maximum). 
AAO = Ascending aorta; AI = Augmentation index; cfPWV = carotid-femoral pulse wave 
velocity; DBP = Diastolic blood pressure; Endo-PAT = Endothelial pulse amplitude testing; hs-
CRP = High sensitivity C-reactive protein; HTN = Hypertension; MMP = matrix 
metalloprotease; MRI = Magnetic resonance imaging; PWV = Pulse wave velocity; SBP = 
Systolic blood pressure.  
  BAV No BAV p Value 
MRI proximal PWV (m/s) 5.2 ± 3.1 4.2 ± 1.1 0.07 
AAO strain (%) 0.37 ± 0.19 0.46 ± 0.21 0.07 
cfPWV (m/s)  5.2 ± 0.8 5.1 ± 1.2 0.75 
AI (%) -7 ± 18 -14 ± 19 0.14 
PAT index 2.13 ± 0.75 2.17 ± 0.75  0.79 
Right arm SBP (mm Hg) 122 ± 12 119 ± 13 0.21 
Right arm DBP (mm Hg) 66 ± 10 64 ± 9 0.47 
24-hour average SBP (mm Hg) 121 ± 12 123 ± 10 0.54 
24-hour average DBP (mm Hg) 68 ± 8 67 ± 7 0.68 
Hypertension Classification   0.86 
   No HTN 22 (55%) 18 (58%)  
   White coat HTN 3 (7%) 1 (3%)  
   HTN/Masked HTN/Anti HTN meds 15 (38%) 12 (39%)  
   Unknown 2 1  
Peak exercise right arm SBP (mm Hg) 174 ± 32 166 ± 34 0.29 
High sensitivity CRP (mg/L) 128 (74, 149) 128 (66, 146) 0.98 
MMP-9/gelatinase B (ng/mL) 488 (91, 4228) 546 (49, 4453) 0.45 
Table S6. Adjustment for Potential Confounders. 
 Unadjusted Model Adjusted Model 
 Coefficient p value Coefficient p value 
CMR proximal PWV (m/s)     
   Balloon dilation -0.76 0.29 -0.49 0.50 
   Stent 0.77 0.26 0.87 0.28 
AAO strain (%)     
   Balloon dilation 0.14 0.02 0.12 0.04 
   Stent -0.02 0.73 0.03 0.68 
cfPWV (m/s)      
   Balloon dilation 0.05 0.84 0.07 0.79 
   Stent -0.20 0.46 -0.54 0.09 
AI (%)     
   Balloon dilation 8.65 0.08 10.6 0.04 
   Stent 18.3 0.001 18.0 0.003 
Endo-PAT index     
   Balloon dilation -0.15 0.48 -0.12 0.59 
   Stent 0.11 0.62 -0.12 0.64 
24-hour average SBP (mm Hg)     
   Balloon dilation -4.99 0.12 -5.24 0.11 
   Stent 0.42 0.89 -2.30 0.36 
24-hour average DBP (mm Hg)     
   Balloon dilation -1.15 0.60 -0.26 0.91 
   Stent 0.48 0.83 -2.57 0.29 
Peak exercise right arm SBP (mm Hg)     
   Balloon dilation -20.1 0.03 -19.3 0.04 
   Stent -0.28 0.97 -3.28 0.76 
Multivariable linear models adjusted for age at treatment and presence of bicuspid aortic valve. 
For each comparison, the surgical group is the reference group. AAO = ascending aorta; AI = 
augmentation index; CMR = cardiac magnetic resonance imaging; DBP = diastolic blood 
pressure; hs-CRP = high sensitivity C-reactive protein; MMP-9 = matrix metalloprotease 9; 
PWV = pulse wave velocity; SBP = systolic blood pressure 
Log hs-CRP (mg/L)     
   Balloon dilation -0.07 0.07 -0.07 0.10 
   Stent 0.02 0.65 0.03 0.54 
Log MMP-9/gelatinase B (ng/mL)     
   Balloon dilation 0.53 0.02 0.64 0.01 
   Stent -0.27 0.22 -0.29 0.28 
